An update from Tonix Pharma (TNXP) is now available.
Tonix Pharmaceuticals is gearing up for a major milestone with the help of EVERSANA, as it prepares to launch its innovative fibromyalgia treatment, Tonmya™, in the U.S. market. The company is on track to submit a New Drug Application to the FDA in the latter half of 2024 and is proactively arranging a pre-NDA meeting with the agency. Investors and market watchers are cautioned to consider the usual risks and uncertainties of such forward-looking statements, although the anticipation for Tonmya’s potential impact on the fibromyalgia medication market is building.
See more data about TNXP stock on TipRanks’ Stock Analysis page.
